Five things to know:
1. During the third quarter, the company rebranded to reflect the expanded applications of its proprietary technology, according to a Dec. 29 news release.
2. The initial portion of U.S. clinical trials for the Ortho-R rotator cuff repair were completed.
3. ChitogenX partnered with California Medical Innovations Institute for collaborative projects in regenerative medicine.
4. The company decided to pursue sales of medical grade chitosan.
5. In December, the company secured $1.2 milloin to fund initiatives and operations related to rotator cuff tear repair.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
